0000000001139261

AUTHOR

Cagakan Ozbalci

showing 1 related works from this author

Biomarkers for Antidepressant Efficacy of Electroconvulsive Therapy: An Exploratory Cerebrospinal Fluid Study

2018

<b><i>Background:</i></b> No candidate biomarkers based on cerebrospinal fluid (CSF) have been identified as prognostic factors in patients with major depression treated with electroconvulsive therapy (ECT), yet. <b><i>Method:</i></b> Following different underlying hypotheses, we analysed baseline CSF levels of markers of neurodegeneration (tau proteins, β-amyloids and neurogranin), elements of the innate immune system (interleukin [IL]-6, neopterin, soluble CD14, soluble CD163, migration inhibitory factor and monocyte chemotactic protein 1), endocannabinoids, sphingolipids and Klotho before ECT in patients with depression (<i>n</i&gt…

MaleOncologymedicine.medical_treatmentchemistry.chemical_compound0302 clinical medicineCerebrospinal fluidElectroconvulsive therapyNeurogranincerebrospinal fluid [Sphingolipids]Electroconvulsive TherapyKlothoGlucuronidaseAged 80 and overtherapy [Depressive Disorder Major]NeopterinInterleukinMiddle AgedPsychiatry and Mental healthTreatment OutcomeNeuropsychology and Physiological Psychologycerebrospinal fluid [Biomarkers]cerebrospinal fluid [Glucuronidase]Biomarker (medicine)AntidepressantFemaleAdultmedicine.medical_specialtyklotho proteinYoung Adult03 medical and health sciencesInternal medicinemental disordersmedicineHumansddc:610Klotho ProteinsBiological Psychiatrycerebrospinal fluid [Nerve Degeneration]AgedDepressive Disorder MajorSphingolipidsbusiness.industrycerebrospinal fluid [Depressive Disorder Major]Immunity Innate030227 psychiatrychemistryNerve Degenerationcerebrospinal fluid [Endocannabinoids]businessBiomarkers030217 neurology & neurosurgeryEndocannabinoidsNeuropsychobiology
researchProduct